{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Beta+Thalassemia+Major&page=2",
    "query": {
      "condition": "Beta Thalassemia Major",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 111,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Beta+Thalassemia+Major&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Beta+Thalassemia+Major&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T22:40:51.723Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00658385",
      "title": "Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Beta Thalassemia Major",
        "Congenital Anemias"
      ],
      "interventions": [
        {
          "name": "GCSF, Central venous line placement, Stem cell Collection (leukapheresis)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2008-04",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2016-11-25",
      "last_synced_at": "2026-10-05T22:40:51.723Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00658385"
    },
    {
      "nct_id": "NCT07640815",
      "title": "Expanded Access Protocol for Gene Therapy Utilizing shmiR Lentivirus Vector to Induce Fetal Hemoglobin in Sickle Cell Disease",
      "overall_status": "TEMPORARILY_NOT_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "David Williams",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "13 Years to 55 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-10-05T22:40:51.723Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07640815"
    },
    {
      "nct_id": "NCT05357482",
      "title": "Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Anemia",
        "Beta Thalassemia"
      ],
      "interventions": [
        {
          "name": "TBI",
          "type": "RADIATION"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "briquilimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Filgrastim (G-CSF)",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Plerixafor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "4 Years to 100 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-05-12",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-10-05T22:40:51.723Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05357482"
    },
    {
      "nct_id": "NCT00661726",
      "title": "Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thalassemia"
      ],
      "interventions": [
        {
          "name": "Decitabine (USAN, INN)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Carelon Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2008-01",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2014-04-25",
      "last_synced_at": "2026-10-05T22:40:51.723Z",
      "location_count": 2,
      "location_summary": "Oakland, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00661726"
    },
    {
      "nct_id": "NCT05356195",
      "title": "Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Beta-Thalassemia",
        "Thalassemia",
        "Genetic Diseases, Inborn",
        "Hematologic Diseases",
        "Hemoglobinopathies"
      ],
      "interventions": [
        {
          "name": "CTX001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "2 Years to 11 Years"
      },
      "enrollment_count": 16,
      "start_date": "2022-05-03",
      "completion_date": "2027-11-14",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-10-05T22:40:51.723Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05356195"
    },
    {
      "nct_id": "NCT05477563",
      "title": "Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Beta-Thalassemia",
        "Thalassemia",
        "Hematologic Diseases",
        "Genetic Diseases, Inborn",
        "Hemoglobinopathies",
        "Sickle Cell Disease",
        "Sickle Cell Anemia"
      ],
      "interventions": [
        {
          "name": "CTX001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 26,
      "start_date": "2022-08-02",
      "completion_date": "2027-06-09",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-10-05T22:40:51.723Z",
      "location_count": 3,
      "location_summary": "New York, New York • Charlotte, North Carolina • Nashville, Tennessee",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05477563"
    },
    {
      "nct_id": "NCT05675436",
      "title": "Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sickle Cell Anemia",
        "Sickle Cell Thalassemia",
        "Sickle Cell Pain",
        "Hbss",
        "Hbsc",
        "Sickle Beta Thalassemia",
        "Sickle Beta Zero Thalassemia",
        "Sickle Cell Syndrome Variant"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "16 Years to 80 Years"
      },
      "enrollment_count": 6,
      "start_date": "2024-05-09",
      "completion_date": "2027-10-27",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-05T22:40:51.723Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05675436"
    },
    {
      "nct_id": "NCT04872179",
      "title": "International Registry of Patients With Alpha Thalassemia",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alpha-Thalassemia",
        "Alpha Thalassemia Major",
        "Alpha Thalassemia Minor"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 500,
      "start_date": "2017-01",
      "completion_date": "2037-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-05T22:40:51.723Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04872179"
    },
    {
      "nct_id": "NCT01522547",
      "title": "Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anemia, Sickle Cell"
      ],
      "interventions": [
        {
          "name": "pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 12,
      "start_date": "2007-08-01",
      "completion_date": "2013-12-01",
      "has_results": false,
      "last_update_posted_date": "2019-11-08",
      "last_synced_at": "2026-10-05T22:40:51.723Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01522547"
    },
    {
      "nct_id": "NCT00480506",
      "title": "Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Thalassemia Major"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2004-04",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2012-02-23",
      "last_synced_at": "2026-10-05T22:40:51.723Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00480506"
    }
  ]
}